

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10527598	
	Filing Date		2005-11-03	
	First Named Inventor	Pierrette Gaudreau		
	Art Unit	1654		
	Examiner Name	Bradley, C.		
	Attorney Docket Number	6165-09602		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10527598
Filing Date	2005-11-03
First Named Inventor	Pierrette Gaudreau
Art Unit	1654
Examiner Name	Bradley, C.
Attorney Docket Number	6165-09602

1	CAMPBELL ET AL. GRF analogs and fragments: correlation between receptor binding, activity and structure. Peptides. 1991;12(3):569-574.	<input type="checkbox"/>
2	CERVINI ET AL. Human growth hormone-releasing hormone hGHRH(1-29)-NH ₂ : systematic structure-activity relationship studies. J Med Chem. 1998;41(5):717-727.	<input type="checkbox"/>
3	FELIX ET AL. Synthesis, biological activity and conformational analysis of cyclic GRF analogs. Int J Pep Protein Res. 1988;32(6):441-454.	<input type="checkbox"/>
4	GAYLINN ET AL. Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone. Mol Endocrinol. 1993;7(1):77-84.	<input type="checkbox"/>
5	HORIKAWA ET AL. Molecular cloning of ovine and bovine growth hormone-releasing hormone receptors: the ovine receptor is C-terminally truncated. Endocrinology. 2001;142(6):2660-2668.	<input type="checkbox"/>
6	IRUTHAYANATHAN ET AL. Dehydroepiandrosterone Restoration of Growth Hormone Gene Expression in Aging Female Rats, in Vivo and in Vitro: Evidence for Actions via Estrogen Receptors. Endocrinology. 2005;146(12):5176-5187.	<input type="checkbox"/>
7	IZDEBSKI ET AL. Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci U.S.A. 1995;92(11):4872-4876.	<input type="checkbox"/>
8	IZDEBSKI ET AL. A method for evaluation of activity of growth hormone-releasing hormone analogues. Neuro Endocrinol. Lett. 2007;28(4):382-385.	<input type="checkbox"/>
9	JETTE ET AL. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005;146(7):3052-3058.	<input type="checkbox"/>
10	LANCE Super-active analogs of growth hormone-releasing factor (1-29)-amide. Biochem Biophys Res Commun. 1984;119(1):265-272.	<input type="checkbox"/>
11	MAYO Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-1744.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10527598
Filing Date	2005-11-03
First Named Inventor	Pierrette Gaudreau
Art Unit	1654
Examiner Name	Bradley, C.
Attorney Docket Number	6165-09602

12	VARGA ET AL. Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(6):1708-1713.	<input type="checkbox"/>
13	ZARANDI ET AL. Synthesis and in vitro and in vivo activity of analogs of growth hormone-releasing hormone (GH-RH) with C-terminal agmatine. Int J Pept Protein Res. 1990;36(6):499-505.	<input type="checkbox"/>
14	ZARANDI ET AL. Potent agonists of growth hormone-releasing hormone. Part I. Int J Pept Protein Res. 1992;39(3):211-217.	<input type="checkbox"/>
15	ZARANDI ET AL. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(12):4610-4615.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.